DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for cervical carcinoma — screening already-approved drugs against its 36-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCervical carcinoma maps to a 36-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for cervical carcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
lipoprotein(a) (LPA) — LPA is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2sdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8TCE · 1.07 Å · ligand (2S)-3-phenyl-2-[(3R)-pyrrolidin-3-yl]propanoic acid (HWF). Experimental structure, not a prediction.
What the evidence adds up to
A 2018 meta-analysis of cervical cancer transcriptome data identified candidate biomarkers and potential therapeutic targets by integrating gene expression profiles with biomolecular networks. The analysis cross-validated differential expression in independent RNA-Seq and miRNA-Seq datasets and demonstrated prognostic power for several reporter biomolecules, including KAT2B, PCNA, CD86, miR-192-5p and miR-215-5p. Novel candidates included ephrin receptors EPHA4, EPHA5, and EPHB2; endothelin receptors EDNRA and EDNRB; nuclear receptors NCOA3, NR2C1, and NR2C2; miRNAs miR-192-5p, miR-193b-3p, and miR-215-5p; transcription factors E2F4, ETS1, and CUTL1; proteins KAT2B, PARP1, CDK1, GSK3B, WNK1, and CRYAB; and metabolites including arachidonic acids. The study did not test any drug.
A 2017 review of molecular pathways in oncogenic HPV and targeted therapies for cervical carcinoma stated that drugs acting on specified molecular targets are at different stages of clinical trials. The review did not name any drug, report any response rate, or provide any survival data.
A 1995 retrospective review of 100 radical hysterectomies for limited cervical cancer compared two time periods (1981–1987 and 1988–1993). Mean operative time remained 199 minutes. Blood product use declined from mean 2.1 to 1.5 units (P < .01). Mean hospital stay fell from 10.6 to 7.4 days (P < .01). Postoperative complication rates decreased significantly (P < .01). The 5-year survival rate remained 91%. Obese patients (≥80 kg) received more transfusions than nonobese patients (2.6 vs 1.6 units; P = .02), but operative time, hospital stay, and complication rates did not differ significantly between weight groups. The authors concluded that surgical treatment of limited cervical carcinoma continues to be safe and effective.
What is still missing: no drug has been tested in a controlled trial for repurposing in cervical cancer based on the transcriptomic targets identified; the 2017 review confirms that targeted therapies remain in early clinical stages with no reported efficacy data; the surgical outcome study is limited to a single institution, retrospective design, and a sample of 100 patients. Funding for biomarker-driven trials, prospective validation of candidate targets, and stratification of patients by molecular subtype are all absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
PLoS ONE · 2018 · 131 citations · open access
Potential biomarkers and therapeutic targets in cervical cancer: Insights from the meta-analysis of transcriptomics data within network biomedicine perspective
AbstractThe malignant neoplasm of the cervix, cervical cancer, has effects on the reproductive tract. Although infection with oncogenic human papillomavirus is essential for cervical cancer development, it alone is insufficient to explain the development of cervical cancer. Therefore, other risk factors such as host genetic factors should be identified, and their importance in cervical cancer induction should be determined. Although gene expression profiling studies in the last decade have made significant molecular findings about cervical cancer, adequate screening and effective treatment strategies have yet to be achieved. In the current study, meta-analysis was performed on cervical cancer-associated transcriptome data and reporter biomolecules were identified at RNA (mRNA, miRNA), protein (receptor, transcription factor, etc.), and metabolite levels by the integration of gene expression profiles with genome-scale biomolecular networks. This approach revealed already-known biomarkers, tumor suppressors and oncogenes in cervical cancer as well as various receptors (e.g. ephrin receptors EPHA4, EPHA5, and EPHB2; endothelin receptors EDNRA and EDNRB; nuclear receptors NCOA3, NR2C1, and NR2C2), miRNAs (e.g., miR-192-5p, miR-193b-3p, and miR-215-5p), transcription factors (particularly E2F4, ETS1, and CUTL1), other proteins (e.g., KAT2B, PARP1, CDK1, GSK3B, WNK1, and CRYAB), and metabolites (particularly, arachidonic acids) as novel biomarker candidates and potential therapeutic targets. The differential expression profiles of all reporter biomolecules were cross-validated in independent RNA-Seq and miRNA-Seq datasets, and the prognostic power of several reporter biomolecules, including KAT2B, PCNA, CD86, miR-192-5p and miR-215-5p was also demonstrated. In this study, we reported valuable data for further experimental and clinical efforts, because the proposed biomolecules have significant potential as systems biomarkers for screening or therapeutic purposes in cervical carcinoma.
Cleveland Clinic Journal of Medicine · 1995 · 3 citations
Radical hysterectomy for cervical cancer: the effect of shorter length of stay on outcome
AbstractBACKGROUND: The surgical treatment for limited cervical cancer (radical hysterectomy and pelvic lymph node dissection) has remained essentially the same for 40 years, but economic pressures have resulted in shorter length of hospital stay, and precautions against infectious diseases have resulted in less use of blood products. PURPOSE: To determine if recent changes in hospital practices have affected outcomes, and if obese patients are at greater risk of complications. METHODS: Retrospective review of 100 surgical cases grouped by time period (1981 through 1987 and 1988 through 1993) and by patient weight (< 80 kg and > or = 80 kg). RESULTS: Comparing the two time periods, the mean operative time remained the same (199 minutes), but use of blood products declined (mean 2.1 vs 1.5 units; P < .01), as did the mean length of hospital stay (10.6 vs 7.4 days, P < .01). The rate of postoperative complications decreased significantly (P < .01), and the 5-year survival rate remained 91%. Obese patients received more blood transfusions than did nonobese patients (2.6 vs 1.6 units; P = .02), but their mean operative time and hospital stay did not significantly differ. The rate of postoperative and long-term complications did not differ significantly between the two weight groups. CONCLUSIONS: Surgical treatment of limited cervical carcinoma continues to be safe and effective.
Advances in Surgical Sciences · 2017 · 1 citations · open access
A Review of the Molecular Pathways of Oncogenic HPV and Targeted the Rapies in Carcinoma of the Uterine Cervix
AbstractCervical carcinoma is a preventable disease based on its etiopathogenesis. This relies highly on its prompt diagnosis and treatment based on effective screening and treatment methods. Knowledge of its molecular pathways will drive the use of targeted therapies in the treatment of the disease. The objectives of this review are: to explore the biology and immunology of HPV; the various molecular pathways through which oncogenic HPV destroys normal cervical cells; and targeted therapies. Several molecular pathways have been identified but the use of drugs to act on specified molecular targets are at different stages of clinical trials.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
